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Abstract
We describe a reference panel of 64,976 human haplotypes at 39,235,157 SNPs constructed using 
whole genome sequence data from 20 studies of predominantly European ancestry. Using this 
resource leads to accurate genotype imputation at minor allele frequencies as low as 0.1%, a large 
increase in the number of SNPs tested in association studies and can help to discover and refine 
causal loci. We describe remote server resources that allow researchers to carry out imputation and 
phasing consistently and efficiently.
Over the last decade, large scale international collaborative efforts have created successively 
larger and more ethnically diverse genetic variation resources. For example, in 2007 the 
International HapMap Project produced a haplotype reference panel of 420 haplotypes at 
3.1M SNPs in 3 continental populations1. More recently, the 1000 Genomes Project has 
produced a series of datasets built using low-coverage whole genome sequencing (WGS), 
culminating in 2015 in a reference panel (1000GP3) of 5,008 haplotypes at over 88M 
variants from 26 world-wide populations2. In addition, several other projects have collected 
low-coverage WGS data in large numbers of samples that could potentially also be used to 
build haplotype reference panels3–5. A major use of these resources has been to facilitate 
imputation of unobserved genotypes into genome-wide association study (GWAS) samples 
that have been assayed using relatively sparse genome-wide microarray chips. As the 
reference panels have increased in number of haplotypes, SNPs and populations, genotype 
imputation accuracy has increased, allowing researchers to impute and test SNPs for 
association at ever lower minor allele frequencies. A succession of methods developments 
have provided researchers with the tools to cope with these increasing larger panels 6–11.
We formed the Haplotype Reference Consortium (HRC) (see URLs) to bring together as 
many WGS datasets as possible to build a much larger combined haplotype reference panel. 
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By doing so, our aim is to provide a single centralized resource for human genetics 
researchers to carry out genotype imputation. Here we describe the first HRC reference 
panel that combines datasets from 20 different studies (Supplementary Table 1). The 
majority of these studies have low-coverage WGS data (4-8X coverage) and are known to 
consist of samples with predominantly European ancestry. However the 1000 Genomes 
Phase 3 cohort, which has diverse ancestry, is also included. This reference panel consists of 
64,976 haplotypes at 39,235,157 SNPs that have evidence of having a minor allele count 
(MAC) greater or equal to 5.
We took the following approach to create the reference panel. We combined existing sets of 
genotype calls from each study to determine a ‘union’ set of 95,855,206 SNP sites with 
MAC >= 2. After initial tests, we decided for this first version of the HRC panel not to 
include small insertions and deletions (indels), since these were very inconsistently called 
across projects. We then used a standard tool to calculate the genotype likelihoods 
consistently for each sample at each site from the original study BAM files (see Methods) 
and make a baseline set of non-LD based genotype calls. We next applied a number of filters 
to remove poor quality sites (see Methods). We restricted this site list to sites with MAC >= 
5 based on the calls made originally by the individual studies, corresponding to a minimum 
minor allele frequency (MAF) of 0.0077%, then added back sites that are present on several 
commonly used SNP microarray chips in GWAS. Sites with lower MAF would be likely to 
be poorly imputed. This site list consisting of 44,187,567 sites exhibited improved quality 
compared to the unfiltered MAC >= 5 site list when assessed by measuring a per sample 
transition-to-transversion (Ts/Tv) ratio (Supplementary Figures 1-2). We also detected and 
removed 301 duplicate samples across the whole dataset (see Methods).
Calling genotypes and phasing using low-coverage WGS data has been a computational 
challenging step for many of the 20 studies providing data. To reduce computation, we 
carried out this step on genotype likelihoods from all 32,611 samples together, and leveraged 
the original separately called haplotypes from each study to help reduce the search space of 
Oxford Phasing Server
https://phasingserver.stats.ox.ac.uk/
Genotype Likelihood calculation scripts
https://github.com/mcshane/hrc-release1
GLPhase
http://www.stats.ox.ac.uk/~marchini/software/gwas/gwas.html
ligateHAPLOTYPES
https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html
Complete Genomics high-coverage WGS genotypes
http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130524_cgi_combined_calls/
1000 Genomes Project OMNI genotypes
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/hd_genotype_chip/ALL.chip.omni_broad_sanger_combined.
20140818.snps.genotypes.vcf.gz
100,000 Genomes Project
http://www.genomicsengland.co.uk/the-100000-genomes-project/
GEMMA
http://www.xzlab.org/software.html
LocusZoom
http://locuszoom.sph.umich.edu/locuszoom/
1000GP3 related samples
ftp://ftp.1000genomes.ebi.ac.uk//vol1/ftp/release/20130502/20140625_related_individuals.txt
SNP chip site lists
http://www.well.ox.ac.uk/~wrayner/strand/
McCarthy et al. Page 2
Nat Genet. Author manuscript; available in PMC 2017 April 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
the calling algorithm (see Methods). We then applied a further refinement step by re-phasing 
the called genotypes using the SHAPEIT3 method12, based on experience from the UK10K 
project, which found this re-phasing approach produced substantially improved imputation 
accuracy when using the haplotypes4. After final genotype calling, we removed a further 
123 samples (see Methods) and filtered out 4,952,410 sites whose MAC after refinement and 
sample removal was below 5, resulting in a final set of 39,235,157 sites and 32,488 samples. 
By measuring genotype discordance of the called genotypes compared to Illumina 
OMNI2.5M chip genotypes available on the 1000 Genomes samples we showed that both 
our site filtering strategy and the increased sample size of HRC led to improved accuracy 
(Supplementary Table 2). For example, we obtained a non-reference allele discordance of 
0.39% on the full HRC dataset with site filtering, compared to 0.67% on the subset of 
1000GP3 samples.
We next carried out experiments to assess and illustrate the downstream imputation 
performance compared to previous haplotype reference panels. To mimic a typical 
imputation analysis, we created a pseudo-GWAS dataset using high-coverage Complete 
Genomics (CG) WGS genotypes on 10 CEU samples (see URLs). We extracted the CG SNP 
genotypes at all the sites included on an Illumina 1M SNP array (Human1M-Duo v3C). 
These were used to impute the remaining genotypes which were then compared to the held 
out genotypes, stratifying results by MAF of the imputed sites. Figure 1 shows that the HRC 
reference panel leads to a large increase in imputation performance when using a 1M SNP 
chip, compared to the 1000GP3 (R2=0.64 vs R2=0.36 at MAF = 0.1%) and also that the re-
phasing step using SHAPEIT3 is worthwhile. HRC imputation at 0.1% frequency provides 
similar accuracy to 1000GP3 imputation at 0.6% frequency. Supplementary Figures 3 and 4 
show the results from a denser (Illumina OMNI 5M) SNP chip and a sparser (Illumina Core 
Exome).
To illustrate the benefits of using the HRC resource, we imputed a GWAS study of 1,210 
samples from the InCHIANTI study13, including 534 that did not contribute to the HRC 
reference panel because they were not sequenced. Imputing using the HRC panel resulted in 
15,501,516 SNPs passing an imputation quality threshold of r2≥0.5 compared to 13,238,968 
variants (11,908,509 SNPs and 1,330,459 indels) when imputing using 1000 Genomes Phase 
3, an increase of over 2 million variants. Taking the intersection of variant sites between the 
two panels to account for the filtering applied to the HRC panel resulted in 13,364,795 SNPs 
and 10,728,322 SNPs with r2≥0.5 for HRC and 1000 Genomes Phase 3 panel, respectively. 
The majority of these additional SNPs occur at the lower frequency range (Supplementary 
Table 3).
We next tested the HRC imputed genotypes for association with 93 circulating blood marker 
phenotypes, including many of relevance to human health such as lipids, vitamins, ions, 
inflammatory markers and adipokines14,15.This analysis highlighted potential novel 
associations at the nominal GWAS significance threshold of 5e-8 (Supplementary Table 4). 
When we repeated the imputation using the HRC panel without the overlapping InCHIANTI 
samples, we obtained similar results (Supplementary Table 4). We took these SNPs forward 
for replication in the SHIP and SHIP-TREND cohorts (see Methods) and found that two of 
the SNPs replicated (Supplementary Table 5). Specifically, we found that SNP rs150956780 
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(MAF= 0.6%) was associated with the Lactic Dehydrogenase phenotype (meta-analysis p-
value = 3.779E-29) and SNP rs147142246 (MAF= 0.6%) was associated with the Potassium 
phenotype (meta-analysis p-value = 8.7E-09). We also found that it is possible for HRC 
imputation to refine signals of association. For example, Figure 2 shows the association 
results of HapMap2, 1000GP3 and HRC based imputation for the α1-antitripsin phenotype 
at the SERPINA1 locus. HRC imputation gives a clear refinement of the signal at the rare 
causal SNP rs28929474 (MAF=0.5%) (Supplementary Table 6), known to predispose to the 
alpha 1 antitrypsin deficiency lung condition emphysema 16,17. Similar results were 
obtained when using the HRC panel that excluded the InCHIANTI samples (data not 
shown).
Since the HRC reference panel combines data from many different studies with a range of 
restrictions on data release we have developed centralized imputation server resources (see 
URLs). Under this model researchers upload phased or unphased genotype data and 
imputation is carried out on central servers. Once completed researchers can download 
imputed datasets. Along similar lines, we have also developed a lower throughput phasing 
server for haplotype estimation of clinical samples with genotypes from high-coverage WGS 
data that takes advantage of rare variant sharing 18 (see URLs). A limited subset of HRC 
haplotypes will be made available for researchers via the European Genome-phenome 
Archive (EGA) for the sole purpose of phasing and imputation.
This first release of the HRC is the largest human genetic variation resource to date and has 
been created via an unprecedented collaboration of data sharing across many groups. We 
envisage continuing to expand the HRC and are currently planning a second HRC release 
differing from the first release in two ways. Firstly, we aim to substantially increase the 
ethnic diversity of the panel, by including data from sequencing studies in world-wide 
sample sets such as the CONVERGE study19, AGVP20 and HGDP21 Secondly, we aim to 
include short insertions and deletions in addition to SNP variants. In the limit of a reference 
panel consisting of the whole human population except the person being imputed, then 
imputation would likely be almost perfect for alleles at any frequency, since the panel would 
contain close relatives that share long and almost identical tracts of sequence. Therefore, we 
do expect to be able to make future gains in imputation performance. In some populations 
that have experienced isolation (like Sardinia or Iceland) we expect to approach this limit 
much faster. Thinking further ahead, we hope to work closely with efforts under way to 
collect large samples of high-coverage sequenced samples such as the UK 100,000 Genomes 
Project (see URLs).
Online methods
Union site list
Every study provided us with their most recent version of their haplotypes in VCF format 
with one VCF for every autosome. For every cohort, bcftools (v0.2.0-rc12) was used to 
create an entire-autosome, SNP-only site list with alternate and total allele count information 
from these per-chromosome haplotypes. Multiallelic SNPs were broken into biallelics using 
‘bcftools norm’. These per-cohort site lists were merged into a single file using an in-house 
Perl script that correctly merges alternate and total allele counts. We created site lists called 
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MAC2 and MAC5 containing only sites with a minor allele count (MAC) across all studies 
of >= 2 and >=5, respectively, using bcftools. These sites lists contained 95,855,206 and 
51,060,347 sites, respectively.
Genotype likelihood calculations
The 'samtools mpileup' command was used to generate genotype likelihoods (GLs) at all 
MAC2 sites on a per sample basis from each sample’s BAM file. The pipeline and software 
versions have been made available online (see URLs). The resulting BCF files were merged 
using the 'bcftools merge' command and the MAC2 sites and alleles extracted using the 
'bcftools call' command. The use of 'bcftools call' here made a baseline set of non-LD based 
genotype calls for each site across all samples. These calls were used for some initial sample 
QC (see Sample filtering section). We calculated GLs on 33,070 samples in total.
Site filtering
We used an ad-hoc method for initial variant filtering which enabled us to identify variants 
that had been filtered out ‘quite often’ by our submitting studies. For each site and for each 
cohort, we labelled the site as “called” in that study if the putative calls from bcftools based 
on GLs exhibited more than one allele in that cohort, or “not called” if it showed no 
variation. We also used the haplotype sets provided by each study to determine whether each 
study had filtered out each site or not using their own internal calling pipeline. To determine 
a threshold of “number of times filtered out”, we stratified the sites according to their called 
status versus their filtered status (Supplementary Figure 5). We also measured the Ts/Tv 
ratio of the set of SNPs for each of these stratified combinations. SNPs corresponding to the 
cells above the red line in the figure were filtered out, removing all cells which had been 
filtered out by more than 4 studies or have Ts/Tv ratio less than 1.7.
We also applied a set of additional site filters as follows. We filtered out sites not on the 
MAC5 site list to restrict the site list to those that could be imputed well. We also filtered out 
sites if (i) any study (apart from 1000 Genomes) had a Hardy-Weinberg Equilibrium (HWE) 
p-value < 10-10, (ii) any study (apart from 1000 Genomes) had an overall inbreeding 
coefficient < -0.1, (iii) a MAF>0.1 with the site being called in fewer than 3 of the studies 
and not called in 1000 Genomes (the latter restriction kept sites present at high frequencies 
in non-European populations that were only called in 1000 Genomes). We also filtered out 
sites called only in the GoNLstudy or IBD cohort. We completely excluded GPC haplotypes 
from this step of the site list creation process.
After applying these filters, the site list comprised of 44,038,997 sites. Finally, we made sure 
that 4,914,335 sites found on a selection of common SNP genotyping arrays and those used 
in the GIANT consortium and the Global Lipids Consortium (Supplementary Table 7) were 
included in the final site list. The final site list after this filtering contained 44,187,567 sites.
Sample filtering
Having used 'bcftools call' to extract sites and alleles, we had a set of baseline non-LD 
genotype calls (see Genotype likelihood calculations section). Based on these calls for 
chromosome 22, some outlier samples were evident and we removed 150 samples showing 
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evidence for fewer than 10,000 non-reference SNPs or more than 10 singletons across the 
chromosome. This left a total of 32,920 samples.
To detect possible duplicates we used the original genotype calls submitted by the individual 
studies. We selected 1000 random sites that (1) were biallelic; (2) had European minor allele 
frequency > 5% in 1000GP3; and (3) had no missing data in any of the individual studies. 
Using the 'bcftools gtcheck' command, we counted the number of genotypes that differed 
between each sample pair. There was a clear set of 269 sample pairs with very few 
genotypes differing over the 1000 sites. We identified these samples as duplicates either 
within or between studies and removed one of the samples in the pair as described in 
Supplementary Table 8. Due to some samples being represented more than twice, there were 
a total of 261 samples removed due to duplicates. Before genotype calling, we also removed 
(i) 9 samples for which we had Complete Genomics data so that we could use these samples 
for testing purposes, (ii) 31 samples from 1000GP3 that were related samples (see URLs), 
(iii) 8 samples from the HELIC, AMD and ProjectMinE studies with sample labeling 
inconsistencies. These filters resulted in 32,611 samples being used for the genotype calling 
and phasing steps.
In addition, after the phasing, 83 samples from the AMD study were removed as the consent 
for these samples had been removed. We also repeated the duplicate detection process on the 
final HRC genotype calls, since some studies increased in size late on within the analysis 
process. This resulted in an extra 40 samples being removed and a total of 32,488 samples in 
the final phased reference panel.
Genotype calling method leveraging existing haplotype calls
We called genotypes from the genotype likelihoods computed on the HRC samples by 
extending the SNPTools22 algorithm to leverage pre-existing haplotypes available from each 
cohort. Like other phasing and calling approaches8,10, SNPTools is an MCMC approach in 
which each sample's haplotypes and genotypes are iteratively updated using the current 
estimates of all other samples. A low-complexity Hidden Markov Model (HMM) with just 
four states is used to update each sample, where the states are a set of four "surrogate parent" 
haplotypes. The MCMC sampler employs a Metropolis-Hastings (MH) step to sample the 
set of surrogate parents. In large sample sizes the search space for these surrogate haplotypes 
is huge and results in low acceptance rates for the sampler. Our extension, called GLPhase 
(see URLs) uses pre-existing haplotypes to restrict the set of possible haplotypes from which 
the MH sampler may choose surrogate parent haplotypes. For each individual, we restrict the 
search space to 200 haplotypes that most closely match the two pre-existing haplotypes of 
the individual using a Hamming distance metric (100 for each haplotype). We run the 
method on chunks of 1,024 sites at a time, which is the default setting for SNPtools. Since 
the pre-existing haplotypes from each study do not contain exactly the same set of sites we 
filled in missing alleles in the pre-existing haplotypes at our site list using the major allele at 
each site.
Restricting the search space in this way allows us to reduce the number of burn-in iterations 
from 56 to 5, the number of sampling iterations from 200 to 95, and the number of MH steps 
taken at each iteration for each individual from 2N to 100, where N is the number of samples 
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being phased. This reduces the complexity of our phasing algorithm from O(N2) to O(N). 
Although our implementation of the Hamming distance search has complexity O(N2), for N 
= 30,000, the impact of the search on run time is small (~5% of run time on each chunk). A 
chunk of 1024 sites can be phased in ~200 minutes using ~1.3GB of RAM. Once sample 
sizes are encountered where the Hamming distance search begins to dominate, our 
implementation could be replaced with O(N log N) clustering algorithms that we have 
implemented within the SHAPEIT3 algorithm12.
To illustrate how important GLPhase was to genotype calling and phasing on such a large 
sample size, we carried out a comparison to Beagle 3.1, Beagle 4.1 and the original 
SNPTools method. We ran all four methods on five randomly selected 1024 site chunks from 
chromosome 20 on the cluster using increasing sample sizes and measured run time. 
Supplementary Figure 6 shows that GLPhase is approximately 100 times faster than the next 
quickest method at the full HRC sample size.
Final phasing and haplotype estimation
We estimated haplotypes from GLPhase genotype calls using SHAPEIT312. Chromosomes 
were phased in chunks consisting of 16,000 variants plus 3,300 variants overlapping with 
neighboring chunks on either side. The non-default command line option -w 0.5 was used 
for SHAPEIT3. Chunks were ligated using the ligateHAPLOTYPES program (see URLs). 
SHAPEIT3 does not handle multiple variants at the same genomic coordinate, so 
multiallelic sites (SNPs with 3 or 4 alleles) were shifted by one or two base pairs for 
rephasing, and then moved back to their original position after chunk ligation.
Evaluation of genotype calling process
We tested the genotype calling process on data from chromosome 20 with different 
combinations of site lists and sample sets to assess both the effects of site filtering and the 
benefits of increasing samples size. We evaluated 3 different site lists: the 1000 Genomes 
Phase 3 set of sites (775,927), our HRC MAC5 site list (1,128,114) and our HRC MAC5 site 
list with additional site filtering (1,006,559). We ran the genotype calling method on 3 
different sets of samples : the 2,525 original 1000 Genomes Phase 3 samples, a subset of 
13,309 HRC samples that we used at an early stage of HRC testing (HRC Pilot) from studies 
1000GP3, AMD, GoNL, GoT2D, ORCADES, SardinIA, FINLAND and UK10K, and the 
near-final full set of 32,905 HRC samples. We called genotypes using GLPhase on each of 
these 9 datasets and examined genotype discordance compared to Illumina OMNI2.5M 
genotypes produced by the 1000 Genomes Project. For this comparison, we focused only on 
genotypes from 365 samples shared across the 3 sample sets and at 42,244 SNP sites. We 
calculated percentage discordance for the 3 possible genotypes consisting of reference 
(REF) and alternate (ALT) alleles as well as an overall non-reference allele discordance rate 
(NRD). Results are shown in Supplementary Table 2.
Downstream imputation performance
We assessed imputation accuracy of 4 different reference panels : 1000 Genomes Phase 3, 
UK10K, and two versions of the HRC reference panel, with and without re-phasing with 
SHAPEIT3. To do this we used high-coverage WGS data made publicly available by 
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Complete Genomics (CG) (see URLs). For the pseudo-GWAS samples we used data from 10 
CEU samples that also occur in the 1000 Genomes Phase 3 samples. These samples were 
removed from the various reference panels before using them to assess imputation 
performance.
Three pseudo-GWAS panels were created based on three chip lists (see URLs) : The Illumina 
Omni 5M SNP array (HumanOmni5-4v1-1_A), the Illumina Omni 1M SNP array 
(Human1M-Duo v3C), and the Illumina Core Exome SNP array 
(humancoreexome-12v1-1_a). For these comparisons we only used sites in the intersection 
of the reference panels to enable a direct comparison.
These pseudo-chip genotypes were used to impute the remaining genotypes which were then 
compared to the held out genotypes, stratifying results by MAF of the imputed sites.
Imputation was carried out using IMPUTE27 which chooses a custom reference panel for 
each study individual in each 2 Mb segment of the genome. We set the khap parameter of 
IMPUTE2 to 1000. All other parameters were set to default values. We stratified imputed 
variants into allele frequency bins and calculated the squared correlation between the 
imputed allele dosages at variants in each bin with the masked CG genotypes (called 
aggregate r2 in Figure 1). Non-reference allele frequency for each SNP was calculated from 
HRC release 1 GLs at MAC>=5 sites. Figure 1 shows the results for the Illumina Omni 1M 
chip. Supplementary Figures 3 and 4 show the results from the Illumina Core Exome chip 
and the Illumina Omni 5M chip respectively.
Details of imputation, association testing and replication in the InCHIANTI study
A total of 1,210 individuals from the InCHIANTI study were genotyped using the Illumina 
Infinium HumanHap550 genotyping array13,14 . Individuals were pre-phased using 
autosomal SNPs after filtering out SNPs with MAF <1%, Hardy-Weinberg p-value <10-04, 
and missingness >1%. SNPs were also removed if they could not be remapped to the 
GRCh37 (hg19) human reference. This resulted in 483,991 SNPs available for pre-phasing. 
Phasing was performed locally using SHAPEIT2 10.
Imputation was performed remotely using the Michigan Imputation Server (see URLs). A 
total of 39,235,157 SNPs and 47,045,346 variants were imputed from the HRC and 1000 
Genomes Phase 3 (v5) reference panels, respectively. An imputation quality threshold of r2 
>0.5 was subsequently applied to both imputation datasets prior to association testing. This 
resulted in 15,501,516 and 13,589,949 variants available for association analysis derived 
from HRC- and 1000 Genomes-based imputation, respectively.
A total of 93 circulating factors available in the InCHIANTI study were double inverse-
normalised, while adjusted for age and sex, prior to association testing14,15. Association 
analysis was performed using a linear mixed model framework as implemented in GEMMA 
(see URLs). Plots of association in Figure 2 were produced using LocusZoom (see URLs).
We attempted to replicate the associations reported in Supplementary Table 3 in the SHIP 
and SHIP-TREND cohorts23. The SHIP samples were genotyped using the Affymetrix 
Genome-Wide Human SNP Array 6.0. The SHIP-TREND samples was genotyped using the 
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Illumina Human Omni 2.5 array. Prior to imputation, duplicate samples (by IBS), samples 
with reported vs. genotyped gender mismatch or samples with a very high heterozygosity 
rate were excluded. Additionally, all monomorphic SNPs, SNPs with duplicate 
chromosomal position, SNPs with pHWE <0.0001 and SNPs with a callrate <95% were 
filtered. Imputation was performed on the Sanger Imputation Service (see URLs) against the 
HRC panel. In total, 4,070 SHIP samples and 986 SHIP-TREND samples were included in 
the imputation of genotypes. Association analyses were conducted using SNPTEST 
v2.5.224.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Performance of imputation using different reference panel.
The x-axis shows the non-reference allele frequency of the SNP being imputed on a log 
scale. The y-axis shows imputation accuracy measured by aggregate r2 when imputing SNP 
genotypes into 10 CEU samples. These results are based on using genotypes from sites on 
Illumina OMNI 1M SNP array was used as pseudo-GWAS data.
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Figure 2. Association signal α1-antitripsin phenotype at the SERPINA1 locus.
Association test statistics on the –log10 p-value scale (y-axis) are plotted for each SNP 
position (x-axis). Three different imputation panels were used : HapMap2 (left), 1000GP3 
(middle), HRC release 1 (right). The SNP rs28929474 is shown as a purple and other SNPs 
are coloured according to the levels of LD (r2) with this SNP (see r2 legend in each subplot)
McCarthy et al. Page 15
Nat Genet. Author manuscript; available in PMC 2017 April 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
